Modality
Multispecific
MOA
IL-23i
Target
SGLT2
Pathway
RNA Splicing
LN
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
~Sep 2019
→ ~Dec 2020
Phase 2
~Mar 2021
→ ~Jun 2022
Phase 3
~Sep 2022
→ ~Dec 2023
NDA/BLA
Mar 2024
→ Feb 2025
NDA/BLACurrent
NCT06813588
999 pts·LN
2024-03→2025-02·Recruiting
999 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-231.1y agoPh3 Readout· LN
Trial Timeline
Q2Q3Q42025
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2025-02-23 · 1.1y ago
LN
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06813588 | NDA/BLA | LN | Recruiting | 999 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 |